NYAGIM Event: Dr. Mark Murcko
ven. 14 décembre à 00:00
Come and join us for our second NYAGIM event! Dr. Mark Murcko, CSO of Relay Therapeutics, will present: "The Good, the Bad and the Fake News: How to Combine Experiments and Theory in Drug Discovery". The presentation will start at 6pm at Rockefeller University.
The networking part will start at 7pm. ABSTRACT
Drug discovery is neither efficient nor effective. Programs usually fail, for many different reasons, and even when successful they take far too long. However, there are a range of behaviors that seem to correlate with increased odds of success. Of note, one can argue that the thoughtful application of a rich mix of technologies leads to insights to guide the discovery process with greater certainty. In the current climate, machine learning and related technologies are widely showcased as holding the promise to revolutionize drug discovery. Of course any computational method will co-exist with a panoply of experimental techniques. For example, when thinking about molecular design, structural techniques (such as crystallography, cryo-EM, NMR, HDX, second harmonic generation) can be applied and the resulting information combined in a near-infinite number of ways with a variety of simulation, affinity prediction, and machine learning techniques. I will discuss some ways in which experiment and theory can be combined for maximum benefit, and some traps to avoid. BIO
Mark Murcko, Ph.D. has directly contributed to seven marketed drugs. He is a Founder, Board member, and was the interim CSO at Relay Therapeutics. In addition, Mark is a senior lecturer in the Department of Biological Engineering at MIT, and has served on numerous scientific advisory boards and corporate boards of directors for a diverse range of organizations, including two NYC-based organizations, Quentis Therapeutics and TDI.
Mark was chief technology officer and chair of the SAB of Vertex
Pharmaceuticals and was responsible for the identification, validation and
implementation of disruptive technologies across R&D. Mark is a co-inventor of the HCV protease inhibitor Incivek (telaprevir), as well as Agenerase (amprenavir) and Lexiva (fosamprenavir), Vertex’s two marketed drugs for the treatment of HIV. In addition, he guided the early efforts of Vertex’s cystic fibrosis program that later produced the marketed drugs Kalydeco (ivacaftor) and Orkambi (lumacaftor/ ivacaftor). He also led the early stages of Vertex's influenza program which lead to pimodivir, currently in Phase 3 trials.
Prior to Vertex, Mark worked at Merck Sharpe & Dohme, where he helped discover multiple clinical candidates, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. One of Merck’s development candidates in this area, dorzolamide, was commercialized in two products, Trusopt and Cosopt. Trusopt was the first marketed drug in pharmaceutical history to result from a structure-based drug design program.
He chaired the 2013 Gordon Research Conference in Medicinal Chemistry
and is currently a member of the Board of Trustees of the GRC. He is a co-
inventor on more than 50 issued and pending patents and has co-authored more than 85 scientific articles. Mark holds a Ph.D. in organic chemistry from Yale University.